注意缺陷多动障碍作为新型冠状病毒肺炎感染的一个风险因素
Attention-Deficit/Hyperactivity Disorder as a Risk Factor for COVID-19 Infection.
作者信息
Cohen Herman Avner, Gerstein Maya, Yaniv Noga, Richenberg Yael, Jacobson Eyal, Marton Shoval, Hoshen Moshe, Shkalim Zemer Vered
机构信息
Pediatric Ambulatory Community Clinic, Petach Tikva, Israel.
Tel-Aviv University, Israel.
出版信息
J Atten Disord. 2022 May;26(7):985-990. doi: 10.1177/10870547211044217. Epub 2021 Oct 20.
OBJECTIVE
To postulate that ADHD is a potential risk factor for COVID-19 infection; to evaluate the COVID-19 risk factor on drug-treated ADHD subjects.
METHODS
A retrospective chart review was performed on ADHD subjects aged 6 to 18 years in Israel, who had undergone at least one COVID-19 test during the study period.
RESULTS
Of the 64,409 subjects included in the study, 6,207 (9.64%) had at least one positive COVID-19 test result, 13,300 (20.65%) were diagnosed with ADHD, and of whom 1,751 (13%) had purchased at least two ADHD medications 3 months prior to COVID-19 testing and were defined as being medically treated. Medically-treated ADHD subjects had a significantly lower likelihood to be infected with COVID-19 than untreated subjects.
CONCLUSION
Untreated ADHD patients seem to constitute a risk group for COVID-19 infection. Drug treatment ameliorates risk of spreading COVID-19 infection within the pediatric population and secondary spread in the general population.
目的
假设注意缺陷多动障碍（ADHD）是新型冠状病毒肺炎（COVID-19）感染的潜在风险因素；评估药物治疗的ADHD患者的COVID-19风险因素。
方法
对以色列6至18岁的ADHD患者进行回顾性病历审查，这些患者在研究期间至少接受过一次COVID-19检测。
结果
在纳入研究的64409名受试者中，6207名（9.64%）至少有一次COVID-19检测呈阳性，13300名（20.65%）被诊断为ADHD，其中1751名（13%）在COVID-19检测前3个月购买了至少两种ADHD药物并被定义为接受药物治疗。接受药物治疗的ADHD患者感染COVID-19的可能性明显低于未治疗的患者。
结论
未治疗的ADHD患者似乎是COVID-19感染的风险群体。药物治疗可降低COVID-19在儿童群体中传播以及在普通人群中二次传播的风险。
Zotero 插件